My NCBISign In
Logo of biotechhealthBiotechnology HealthcareLatest IssueBiotech NewsSubmit an Article

Volume 9(1);  Spring 2012

Cover Story

Consolidation Redux

New Life for PBMs?

PBM Consolidation: Better Pricing or Just Less Competition?: The growth of specialty pharmaceuticals, including biologics, is forcing payers and employers to look at cost-saving strategies for managing those drugs. How will they do it if only one large PBM rules the specialty pharmacy network?
ED SILVERMAN
Biotechnol Healthc. 2012 Spring; 9(1): 10–14.
PMCID:
PMC3351886
Full Text PDF–1003K

Departments

Drug Track

Clinical Trials, Research, and FDA Findings
Michael D. Dalzell
Biotechnol Healthc. 2012 Spring; 9(1): 6–7.
PMCID:
PMC3351885
Full Text PDF–409K

Index

Editorial Index

Biotechnology Healthcare’s 2011 Editorial Index
Biotechnol Healthc. 2012 Spring; 9(1): 30–31.
PMCID:
PMC3351889
Full Text PDF–404K

Openers

They’re Here … Now!
KATHERINE T. ADAMS
Biotechnol Healthc. 2012 Spring; 9(1): 1.
PMCID:
PMC3351887
Full Text PDF–495K

Personalized Medicine

Saving Dollars, Preventing Disappointment
BOB CARLSON
Biotechnol Healthc. 2012 Spring; 9(1): 28–29.
PMCID:
PMC3351890
Full Text PDF–438K

The Federal Line

Finding the Right Formula for Bundled Payments: Could reimbursements edge out biologics?
JOHN CARROLL
Biotechnol Healthc. 2012 Spring; 9(1): 8–9.
PMCID:
PMC3351891
Full Text PDF–442K

Trends

Oncology Costs Must Be Reined In, Say Payers
Katherine T. Adams
Biotechnol Healthc. 2012 Spring; 9(1): 33.
PMCID:
PMC3351888
Full Text PDF–404K

Feature Articles

Business

Can Diagnostics Become Economically Viable?

In Search of the Perfect Business Model: As personalized medicine moves into the mainstream, makers of diagnostics must face a new economic reality. How to develop a value proposition in a healthcare market that is becoming increasingly elastic?
BOB CARLSON
Biotechnol Healthc. 2012 Spring; 9(1): 20–23.
PMCID:
PMC3351884
Full Text PDF–761K

Clinical

The Highly Complex Path for Biosimilars

Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety.
ERWIN A. BLACKSTONE, JOSEPH P. FUHR, Jr.
Biotechnol Healthc. 2012 Spring; 9(1): 24–27.
PMCID:
PMC3351893
Full Text PDF–484K

Q&a

A Conversation With Cheryl Larson: Vice President, Midwest Business Group on Health
Michael D. Dalzell
Biotechnol Healthc. 2012 Spring; 9(1): 16–19.
PMCID:
PMC3351892
Abstract Full Text PDF–477K
Articles from Biotechnology healthcare are provided here courtesy of MediMedia, USA
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk